Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific Antibody
Etentamig is an investigational B-cell maturation antigen (BCMA) x CD3 bispecific T-cell engager, composed of a low-affinity CD3 binding domain, potentially reducing cytokine release syndrome (CRS) and infections, a high-avidity bivalent BCMA-binding domain, and retained FcRn binding supporting monthly (Q4W) dosing after a single step-up dose (SUD). We report long-term efficacy and safety from the ongoing, open-label, phase 1 (dose escalation/expansion; NCT03933735) and Arm A of the phase 1b (NCT05650632) studies of etentamig in adult patients with relapsed/refractory multiple myeloma, triple-class exposure, and ≥3 prior lines of therapy (LoT). In phase 1, patients received etentamig 60 mg Q4W or 40 mg Q3W, and in phase 1b, a SUD on Day 1 and 60 mg Q4W on Day 4. Among 146 patients (median age: 68 years; median [range] prior LoT: 4 [3-23]), median follow-up was 13 months (range: 1-48). Objective responses and ≥ very good partial responses occurred in 66% and 54% of patients. Median duration of response and progression-free survival were not reached. Pooled data suggest etentamig has a manageable safety profile, with Grade 3/4 neutropenia and infection occurring in 38% and 23% of patients. In phase 1b Arm A (n=23), overall CRS incidence was 30% (26% Grade 1; 4% Grade 2) with modified dexamethasone premedication and 1 SUD; median onset was 22.3 hours (range: 5.5-29.6) hours, with resolution in 20.7 hours (range: 1.8-131.7). Etentamig's molecular design may be associated with the observed clinical efficacy and tolerability while also potentially supporting extended dosing intervals.
Authors
- Katja Christina Weisel (ORCID: https://orcid.org/0000-0001-9422-6614)
- Shaji Kunnathu Kumar (ORCID: https://orcid.org/0000-0001-5392-9284)
- Saurabh Chhabra (ORCID: https://orcid.org/0000-0001-9117-8696)
- Emma J Searle (ORCID: https://orcid.org/0000-0002-3942-3081)
- Cesar Rodriguez (ORCID: https://orcid.org/0009-0009-8240-5469)
- Hila Magen (ORCID: https://orcid.org/0000-0002-3990-394X)
- Anita D’Souza (ORCID: https://orcid.org/0000-0002-1092-5643)
- Muhamed Baljević (ORCID: https://orcid.org/0000-0002-0630-8458)
- Neha Korde (ORCID: https://orcid.org/0000-0002-5538-4318)
- Rajvineeth Kumar Pothacamury
- Chetasi Talati (ORCID: https://orcid.org/0000-0002-2246-213X)
- Alfred Chung (ORCID: https://orcid.org/0000-0003-0196-5456)
- Aarif Ahsan
- Anders Svensson
- Peter VOORHEES
- Eben Isaac Lichtman
- Claudie Hecquet
- Hana Safah
- Ravi Vij
- John T. Mckay
- Valerie Robinson (ORCID: https://orcid.org/0009-0000-1935-654X)
- Carli Allendorf
- Hira Mian
Institutions
- University of North Carolina at Chapel Hill (US)
- Atrium Health Wake Forest Baptist (US)
- Our Lady of the Lake Regional Medical Center (US)
- Froedtert Hospital (US)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Tel Aviv University (IL)
- University of California, San Francisco (US)
- Washington University in St. Louis (US)
- Sheba Medical Center (IL)
- University of Manchester (GB)
- AbbVie (United States) (US)
- University Medical Center Hamburg-Eppendorf (DE)
- Mayo Clinic in Arizona (US)
- The Christie NHS Foundation Trust (GB)
- Wake Forest Baptist Comprehensive Cancer Center (US)
- UNC Lineberger Comprehensive Cancer Center (US)
- Medical College of Wisconsin Cancer Center (US)
- Wake Forest University Health Sciences (US)
- Wake Forest University (US)
- University of Arkansas for Medical Sciences (US)
- McMaster University (CA)
Publication Details
- Journal
- Blood
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1182/blood.2026034590
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00